Outcome of Board meeting held on 18th July 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Kerala Ayurveda Ltd, at its meeting on 18 July 2025, approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 (Q1 FY26), along with a Limited Review Report carrying an unmodified opinion. Standalone revenue from operations rose to Rs. 17.57 crore from Rs. 16.40 crore in the year-ago quarter, while the company swung to a standalone profit after tax of Rs. 2.07 crore versus a loss of Rs. 1.29 crore, mainly supported by a Rs. 8.04 crore one-time gain from sale of immovable property booked under other income. On a consolidated basis, revenue from operations grew to Rs. 28.61 crore and profit after tax (after minority interest) rose to Rs. 1.99 crore from Rs. 0.32 crore. The board also cleared a Postal Ballot notice seeking shareholder approval for continuation of two non-executive directors, appointment of a new independent director, an increase in borrowing limits under Section 180(1)(c), and material related-party transactions with Katra Holding Pvt Ltd and Katra Phytochem (India) Pvt Ltd.
The reported profit turnaround is largely driven by a one-off property sale gain rather than a meaningful improvement in core operations, so underlying business momentum remains weak. Shareholders will need to vote on higher borrowing limits and related-party transactions with group entities, which could affect future leverage and capital allocation.